PubRank

Jaroslaw P Maciejewski

Author PubWeight™ 181.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010 8.87
2 Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009 4.64
3 Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012 4.15
4 Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2007 3.89
5 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008 3.51
6 Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med 2015 3.42
7 Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2007 3.13
8 Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012 2.88
9 Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2008 2.87
10 Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 2.76
11 Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008 2.64
12 STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012 2.55
13 CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011 2.52
14 Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012 2.51
15 SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012 2.50
16 In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004 2.47
17 Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011 2.47
18 Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 2013 2.24
19 Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 2013 2.22
20 An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011 2.16
21 Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010 2.13
22 Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013 2.12
23 Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009 2.03
24 Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006 1.90
25 SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS One 2007 1.87
26 Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013 1.80
27 CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007 1.80
28 Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002 1.72
29 Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013 1.71
30 Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004 1.70
31 Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013 1.68
32 New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009 1.68
33 Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood 2010 1.62
34 Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 2012 1.61
35 Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011 1.59
36 STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood 2013 1.59
37 Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006 1.58
38 Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst 2014 1.56
39 Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res 2011 1.42
40 Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol 2012 1.40
41 Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008 1.39
42 Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 2006 1.36
43 Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood 2005 1.34
44 Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 2013 1.34
45 Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 2012 1.33
46 Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 2009 1.32
47 Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2005 1.30
48 SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood 2011 1.27
49 Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2010 1.25
50 Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood 2011 1.20
51 HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002 1.19
52 Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006 1.18
53 Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010 1.14
54 Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 2012 1.13
55 Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer 2010 1.12
56 Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J Haematol 2010 1.11
57 Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 2012 1.11
58 Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood 2013 1.10
59 Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica 2009 1.10
60 Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res 2009 1.09
61 Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest 2014 1.09
62 Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 2011 1.07
63 Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program 2011 1.07
64 Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002 1.05
65 Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol 2007 1.05
66 Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther 2010 1.05
67 Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol 2013 1.04
68 Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 2007 1.04
69 Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood 2002 1.03
70 Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol 2012 1.03
71 Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood 2002 1.01
72 Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes. Curr Stem Cell Res Ther 2007 0.99
73 Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. Cell Cycle 2006 0.98
74 Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res 2007 0.98
75 Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol 2004 0.98
76 Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Exp Hematol 2008 0.98
77 Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases. Hematology 2003 0.98
78 Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol 2011 0.97
79 Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica 2014 0.97
80 Human cytomegalovirus persists in myeloid progenitors and is passed to the myeloid progeny in a latent form. Br J Haematol 2004 0.97
81 Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood 2002 0.96
82 Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol 2006 0.96
83 Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol 2009 0.96
84 T-large granular lymphocyte leukemia: current molecular concepts. Hematology 2006 0.94
85 Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. Br J Haematol 2002 0.92
86 Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist 2011 0.92
87 Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia. Cancer 2010 0.92
88 Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res 2012 0.92
89 A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer 2007 0.91
90 FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res 2009 0.91
91 Detection of mature T-cell leukemias by flow cytometry using anti-T-cell receptor V beta antibodies. Am J Clin Pathol 2003 0.91
92 Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res 2010 0.90
93 Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 2011 0.88
94 Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes. J Am Soc Nephrol 2008 0.88
95 A mechanistic overview of TET-mediated 5-methylcytosine oxidation. Biochem Biophys Res Commun 2013 0.88
96 CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrPc). Exp Hematol 2003 0.87
97 The relationship of aplastic anemia and PNH. Int J Hematol 2002 0.87
98 Altered lipid raft composition and defective cell death signal transduction in glycosylphosphatidylinositol anchor-deficient PIG-A mutant cells. Br J Haematol 2008 0.87
99 Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med 2014 0.87
100 Superior growth of glycophosphatidy linositol-anchored protein-deficient progenitor cells in vitro is due to the higher apoptotic rate of progenitors with normal phenotype in vivo. Exp Hematol 2002 0.86
101 High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp Hematol 2007 0.86
102 Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer 2002 0.85
103 Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia. Leuk Res 2012 0.85
104 Molecular analysis of alloreactive CTL post-hemopoietic stem cell transplantation. J Immunol 2007 0.84
105 Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. Blood 2003 0.84
106 A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 2010 0.84
107 Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant 2010 0.83
108 Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. Am J Hematol 2013 0.83
109 Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes. Exp Hematol 2005 0.83
110 HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis 2011 0.82
111 A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer 2011 0.82
112 CDR3 spectratyping identifies clonal expansion within T-cell subpopulations that demonstrate therapeutic antitumor activity. Surgery 2004 0.82
113 Molecular TCR diagnostics can be used to identify shared clonotypes after allogeneic hematopoietic stem cell transplantation. Exp Hematol 2004 0.81
114 The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? Expert Rev Hematol 2013 0.81
115 Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol 2007 0.81
116 Efficient identification of T-cell clones associated with graft-versus-host disease in target tissue allows for subsequent detection in peripheral blood. Br J Haematol 2005 0.81
117 Molecular lesions in childhood and adult acute megakaryoblastic leukaemia. Br J Haematol 2011 0.81
118 Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genet Cytogenet 2008 0.80
119 Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. Leuk Res 2011 0.80
120 Paroxysmal nocturnal hemoglobinuria. Int J Hematol 2005 0.80
121 Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol 2013 0.80
122 Genomic instability in bone marrow failure syndromes. Am J Hematol 2004 0.80
123 Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res 2012 0.80
124 Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007 0.80
125 Is there a direct effect of antithymocyte globulin on hematopoiesis? Hematol J 2004 0.78
126 MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia. Haematologica 2010 0.77
127 Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria. Haematologica 2011 0.76
128 Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. Am J Surg Pathol 2016 0.75
129 Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies. Leuk Res 2012 0.75
130 Postsplenectomy thromboembolic disease in congenital sideroblastic anaemia. BMJ Case Rep 2010 0.75
131 Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms. Int J Hematol 2015 0.75
132 Concurrent juvenile myelomonocytic leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS. Pediatr Blood Cancer 2013 0.75
133 Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F. Hum Pathol 2008 0.75
134 Clinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation. Hematology 2004 0.75
135 High rate of both hematopoietic and solid tumors associated with large granular lymphocyte leukemia. Leuk Lymphoma 2014 0.75
136 Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nat Immunol 2017 0.75
137 T/NK large granular lymphocyte leukemia and coexisting monoclonal B-cell lymphocytosis-like proliferations. An unrecognized and frequent association. Am J Clin Pathol 2010 0.75